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Abstract 
Clinical risk factors explain only a fraction of the variability of estimated glomerular filtration 
rate (eGFR) decline in people with type 2 diabetes. Cross-omics technologies by virtue of 
a wide spectrum screening of plasma samples have the potential to identify biomarkers for 
the refinement of prognosis in addition to clinical variables.  
We utilized proteomics, metabolomics and lipidomics panel assay measurements in 
baseline plasma samples from the multinational PROVALID study (PROspective cohort 
study in patients with type 2 diabetes mellitus for VALIDation of biomarkers) of people with 
incident or early chronic kidney disease (median follow-up 35 months, median baseline 
eGFR 84 mL/min/1.73m2, urine albumin-to-creatinine ratio 8.1 mg/g). In an accelerated 
case-control study, individuals with stable eGFR course (n=258, median eGFR change 0.1 
mL/min/year) were compared to individuals with rapid eGFR decline (n=223, median eGFR 
decline -6.75 mL/min/year) using Bayesian multivariable logistic regression models to 
assess the discrimination of eGFR trajectories. 
The analysis included 402 candidate predictors and showed two protein markers (KIM1, 
NTproBNP) to be relevant predictors of the eGFR trajectory with baseline eGFR being an 
important clinical covariate. The inclusion of metabolomics and lipidomics platforms did not 
improve discrimination substantially. Predictions using all available variables were 
statistically indistinguishable from predictions using only KIM1 and baseline eGFR (area 
under the receiver operating characteristic curve 0.63).  
In conclusion, the discrimination of eGFR trajectories in people with incident or early 
diabetic kidney disease and maintained baseline eGFR was modest and the protein marker 
KIM1 was the most important predictor.  
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Translational Statement 
Considerable funds have been used in the search for prognostic biomarkers in the 
field of chronic kidney disease (CKD), specifically in people with diabetes mellitus 
type 2, but no single biomarker is used routinely for risk prediction yet due to low 
explanatory power. Therefore, given the widely available multiomics analyses 
nowadays, it is appealing to use a wider spectrum of biomarkers for prognosis. 
However, our study suggests that even using multiomics derived biomarker 
candidates, there is currently no clinically useful multivariable panel of plasma 
biomarkers that may be recommended for prediction of future eGFR loss in early 
CKD stages. 
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Introduction 
The global burden of chronic kidney disease (CKD) in persons with type 2 diabetes is 
increasing (1). The progression of CKD in these individuals is highly inconsistent and 
clinical risk factors can only explain some of the variability (2; 3). Refinement of the 
prognostic precision using biomarkers would allow for a more individualized risk 
assessment and personalized therapy (4; 5).  
Several large consortia have been set up to investigate the utility of such novel 
markers derived from omics experiments (SysKid, RHAPSODY, SUMMIT, BEAt-
DKD) (6-8). Although several markers were univariably found to be statistically 
significantly associated with estimated glomerular filtration rate (eGFR) trajectories, 
the potential coregulation and collinearity have not been explicitly addressed in most 
of these studies. Additionally, the explained variability of eGFR prediction of most 
marker panels in addition to clinical risk factors was generally found to be low (9). 
The SUMMIT consortium addressed some of these issues and found that two protein 
biomarkers, Kidney Injury Molecule-1 (KIM1) and Beta-2-Microglobulin (B2M), 
performed equally well as a considerably larger panel adjusted for clinical risk factors 
in predicting rapid decline of eGFR (10). 
Novel technologies nowadays allow for a simultaneous determination of a large 
group of potential progression risk markers derived from proteomics, metabolomics 
and lipidomics analyses (11; 12). However, the combined analysis of the different 
omics layers to study their association with renal function decline has not been 
performed yet. Therefore, the objective of the current study was to identify if and 
which type of biomarkers improve discrimination of different eGFR trajectories in 
early stage CKD patients with type 2 diabetes on top of clinical risk factors. To 
achieve this goal, innovative statistical methods had to be developed and applied to 
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account for the challenging nature of the data with relatively few study outcomes and 
the complex, largely unknown coregulation of the biomarker candidates. At the same 
time, clinically established risk factors needed to be considered in the analysis. We 
therefore applied a Bayesian approach for regularized regression models which 
integrated clinical covariates and explorative multiomics marker with focus on the 
metabolomics and lipidomics platforms to refine the discrimination of individual eGFR 
courses. This study was conducted by the BEAt-DKD investigators (Biomarker 
Enterprise to Attack DKD; https://www.beat-dkd.eu/).  
Results  
We assessed the discrimination of eGFR trajectories in an accelerated case-control 
study by comparing 223 fast progressing and 258 stable individuals selected from a 
cohort of people with type 2 diabetes and early or incident CKD (cohort selection is 
summarized in Supplementary Figure S1, eGFR trajectories are depicted in 
Supplementary Figure S2). Demographics are presented in Table 1, which shows 
balanced covariates between the two groups. In total, 402 predictors for 481 persons 
were evaluated in our study: 10 clinical covariates, 15 protein, 180 metabolite and 
197 lipid biomarkers. Protein and metabolite markers had few missing values (below 
10% missing for all biomarkers), lipids were restricted to those with at least 66% 
completeness. A breakdown of biomarkers used in this analysis and their availability 
is given in Supplement section 3. The overall correlation matrix is shown in 
Supplementary Figure S3. All analyses were based on Bayesian multivariable logistic 
regression models for the outcome of interest (fast progression versus stable 
course). 
Clinical Model  
As a baseline for the evaluation of more elaborate models we fitted a model 
comprising only clinical covariates using weakly informative Student-t prior 
8 
 
distributions, which corresponded to a standard frequentist analysis of the data (see 
Supplementary Table S1). The results indicated that the clinical risk factors by 
themselves were not sufficient to discriminate fast progressing and stable individuals 
(Area under the receiver operating characteristic curve AUROC 0.55, 95% Bayesian 
credible interval BCI [0.46, 0.64], Table 2 and Supplementary Figure S4).  
To identify important predictors we employed shrinkage priors for all subsequent 
analyses. For the clinical model, this affected the coefficient estimates and shrank 
almost all standardized odds ratios for fast progression (sOR) to unity but did not 
change the discriminative ability (AUROC unchanged at 0.55 [0.46, 0.64], Table 2 
and Supplementary Figure S5).  
Single Biomarker Group Analysis 
Regarding models which included only a single group of biomarkers, the pre-selected 
proteomics markers performed best in terms of AUROC (0.63 [0.51, 0.76], Table 2 
and Supplementary Figure S6). KIM1 (sOR 1.52 [1.17, 1.92]) and NTproBNP (sOR 
1.28 [0.99, 1.57]) had the largest marginal effects with high posterior probability for a 
sOR larger than unity. The metabolomics (AUROC 0.58 [0.47, 0.69], Table 2 and 
Supplementary Figure S7) and lipidomics panels (AUROC 0.54 [0.46, 0.63], Table 2 
and Supplementary Figure S8) achieved similar performance as the clinical model. 
However, for these two large biomarker panels none of the candidate predictors 
showed large marginal effect sizes, likely due to correlation of the estimated variable 
effects.  
Combined Analysis 
The main structured model with shrinkage priors accommodating the group structure 
of the data and comprising all 402 candidate predictors (AUROC 0.63 [0.53, 0.74]) 
performed comparably to the protein subpanel and was robust regarding parameter 
settings (Supplementary Figure S9). We present the top 15 predictors in terms of 
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sOR in Figure 1 and Supplementary Table S2. Baseline eGFR (sOR 2.23 [1, 3.4]) 
and KIM1 (sOR 1.59 [1.13, 2.09]) were the only predictors for which the associated 
95% BCI excluded unity. Across all sensitivity analyses and models, KIM1 was the 
single most robust marker, for which the effect was largely unaffected by the 
presence of other variables in the model. The protein marker NTproBNP (sOR 1.28 
[0.97, 1.65]), even though its 95% BCI included unity, was also consistently found to 
have more than 90% posterior probability for a sOR larger than unity, regardless of 
choice of prior and other variables in the model. The role of baseline eGFR was 
subtle. Its apparent importance may partly be explained by our study design, as 
individuals with high eGFR at baseline possibly had a higher likelihood for declining 
eGFR trajectories and for having been selected as cases than individuals whose 
eGFR was already very low to begin with. Even though baseline eGFR was 
statistically indistinguishable between the person groups (Table 1) and did not have a 
marginal effect in the clinical model (sOR 1.01 [0.9, 1.2]), it became important when 
adjusted for correlated markers such as CystatinC and several metabolite markers. 
Each of these variables alone did not well discriminate fast progressing and stable 
individuals but mutual adjustment in the model led to increased effect sizes with large 
uncertainty, as observed in Figure 1. Nevertheless, the overall contribution of eGFR 
correlated markers to discrimination remained low. This is illustrated in Figure 2 
which shows the change of AUROC while limiting the number of predictors in the 
model. KIM1 provided the largest increase in AUROC of any single marker. Together 
with baseline eGFR and NTproBNP the discrimination performance was comparable 
to the full panel of clinical covariates and biomarkers.  
Sensitivity Analysis  
Excluding baseline eGFR as a covariate resulted in a drop in effect size for most 
variables, including duration of diabetes at study entry, but KIM1 and NTproBNP 
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were largely unaffected (Supplementary Figure S10). The discrimination performance 
was slightly lower than for the main structured model (AUROC 0.61 [0.49, 0,72]). 
Changing the coefficient priors to be uninformed of the predictor grouping structure 
led to larger marginal effects for the metabolite and lipid markers, with little changes 
for the top proteomics and clinical variables (Supplementary Figure S11). The 
increased effect sizes were due to less regularization for the larger biomarker 
platforms, which, however, did not increase performance compared to the main 
structured model (AUROC 0.6 [0.48, 0.71]). Regarding the added value of the novel 
biomarker platforms on top of clinical variables and pre-selected proteomics 
biomarkers, none of the metabolite or lipid markers showed consistent effect sizes. 
These results were confirmed in the sensitivity analysis based on principal 
component analysis (Supplementary Figures S12 and S13). While some of the 
principal components showed larger effects than any of the single markers they were 
composed of, discrimination did not differ from the main structured model (AUROC 
0.64 [0.55, 0.74]).  
Discussion 
In this innovative study we used a Bayesian approach to assess the added value of 
biomarkers derived from cross-omics experiments when used together with clinical 
covariates in baseline samples of a prospective cohort study of individuals with type 2 
diabetes and incident or early diabetic CKD. The purpose of the study was to determine 
if lipid, metabolite, or protein biomarkers could enhance prognostication of future 
disease trajectories. We found that clinical variables by themselves were not sufficient 
to discriminate between fast progressing and stable individuals in this cohort, while two 
protein markers, KIM1 and to lesser extent NTproBNP, robustly contributed to the 
discrimination of the eGFR trajectories. Furthermore, when used together with the 
proteomics biomarkers and clinical variables, the metabolite and lipid biomarkers did 
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not increase discriminative ability of the models. Due to strong correlations, these 
biomarkers seem exchangeable – a model with a few of them performs as well as a 
model considering the entire platform. The overall discrimination and therefore the 
clinical utility for prediction of eGFR decline was low. Inclusion of urinary albumin 
excretion did not increase discrimination which may be explained by the low amount 
of albuminuria in this study cohort of people with early stage disease and maintained 
kidney function. 
Other studies investigated the statistical performance of large panels of protein 
biomarkers for predicting disease progression. Gerstein and colleagues used a large 
protein panel in almost 7500 participants of the ORIGIN trial to identify suitable 
prognostic markers of eGFR slope. The investigators identified 13 markers that were 
independently associated with progression. The explained variance of the marker plus 
clinical parameters model was 0.155 (95% confidence interval [0.139, 0.172]) 
(Gerstein H, Pare G, McQueen M et al “Novel Biomarkers Predicting Renal Dysfunction 
in People with Dysglycemia in the ORIGIN Trial”. Abstract for American Diabetes 
Association's 79th Scientific Sessions San Francisco, CA, 2019). However, this 
elegant study used only protein biomarker candidates to estimate eGFR slope. In 
general, only few studies investigated the capacity of multiomics panels to discriminate 
individuals with fast eGFR loss versus stable course. 
Previously Bansal and colleagues measured two markers (NTproBNP and troponin T) 
in 3752 participants free of heart failure in the Cardiovascular Health Study (13). 
Participants in the highest quartile of NTproBNP concentrations (>237 pg/ml) exhibited 
a 67% higher risk of rapid eGFR decline and 38% higher adjusted risk of incident CKD 
compared to stable individuals (adjusted hazard ratio for incident CKD 1.38; 95% 
confidence interval [1.08, 1.76]). Troponin T was not statistically associated with this 
outcome. 
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KIM1 in combination with B2M, the latter not being measured in our study, were also 
found to be key predictors of eGFR loss in an analysis of the SUMMIT investigators 
(10).  
Metabolomics technologies can measure thousands of small sized biochemicals, but 
its utility for biomarker discovery in CKD remains unclear. The US based CKD 
biomarkers consortium recently showed in a metabolomics analysis of 49 proteinuric 
patients with advanced CKD (eGFR <60 mL/min/1.73m2) that several hundred 
metabolites were inversely correlated with eGFR in a cross-sectional study, but the 
intraindividual variability was high (14). Some of these investigators showed previously 
that many metabolites were associated with incident CKD in African American persons 
and identified two metabolites as best candidates to predict CKD risk (15). 
Lipidomics is an emerging field and together with genomics and proteomics allows for 
a better understanding of cellular physiology and pathology. Prades and colleagues 
showed that this technology can be used to identify tissue specific patterns of panels 
(16). Therefore, it is appealing to identify lipid biomarker candidates for complex 
biological processes such as the progression of diabetic kidney disease. Here we 
applied all three technologies, proteomics, metabolomics and lipidomics, to the same 
baseline samples from individuals with early diabetic kidney disease using innovative 
analytical methods.  
The findings of the current study are in line with and extending our previous work (9), 
which used mixed linear models for the longitudinal eGFR values based on clinical 
covariates and protein biomarkers. There, KIM1 and NTproBNP were also found to 
contribute to the prediction of the eGFR slope. Baseline eGFR showed a dominating 
effect in terms of explained variation, as it provided the natural starting point for the 
future eGFR trajectory and because effects on the eGFR slope contributed less to the 
models’ explained variation than effects on baseline eGFR. In this current analysis, we 
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were able to further dissect the role of baseline eGFR and found that its effect strongly 
correlated with effects of other biomarkers such as CystatinC and several metabolites, 
reflecting a persons’ disease state at baseline.  
Our study has some limitations. Missing biomarker measurements were mitigated by 
the use of multiple imputation. The early disease stage of the participants, which may 
limit the detection of progression specific signals, was chosen on purpose as risk 
prediction is likely most useful in early disease states when potential interventions 
exhibit the greatest benefit.  
The definition of our outcome and the study design with exploratory aspects may be 
seen as both an advantage and a limitation of the study. By carefully investigating the 
patient’s trajectories over the relatively short follow-up of around three and a half years 
in the PROVALID cohort, we attempted to select robustly identifiable eGFR courses 
on the opposite sites of the prognostic spectrum, which helped to mitigate the issue of 
limited sample size and to increase statistical power. However, by selecting based on 
the outcome, a possible source of bias is introduced towards larger effect sizes. Since 
our results yield low discrimination and effects which are in agreement with other 
studies conducted, we argue that this bias should be of little concern. 
Strengths of our study include the precise clinical characterization of the prospective 
PROVALID cohort from which we selected individuals (17). Our statistical approach 
allowed us to integrate multiomics data. By foregoing a pure variable selection based 
approach we were able to carefully discuss the complex interplay of biomarkers and 
clinical variables. 
In conclusion, the discrimination of eGFR trajectories using baseline circulating 
multiomics derived biomarkers in combination with clinical parameters was modest, 
with the two protein markers KIM1 and to lesser extent NTproBNP emerging as the 
most relevant biomarker candidates. The findings for metabolite and lipid biomarkers 
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may help to identify new targets and pathways for pharmaceutical intervention to treat 
individuals with early progressive CKD and mitigate their future renal decline to end 
stage renal disease and dialysis. 
Methods 
Study Design and Cohort 
The motivation for this study was the careful evaluation of known protein biomarker 
as well as the exploration of further metabolite and lipid candidates. We employed an 
accelerated case-control design which selected individuals from the opposite ends of 
the prognostic spectrum and hence made associated variables easier to detect 
because the effects are more pronounced than in the full cohort. The associated 
increase in statistical power has been studied in (18). Our study cohort was derived 
from PROVALID, a prospective multinational cohort study of persons with type 2 
diabetes and incident or early CKD with annual follow-up (19; 20). In total 2560 
participants from three countries were available for the present analysis. After 
excluding people with less than 720 days of follow-up (FU) we estimated the annual 
change in eGFR via slopes from individual linear regressions. Persons were then 
grouped according to the slope quintiles. In a final screening step, individuals for 
whom the slope was deemed unsteady due to large uncertainty of the estimated 
slope and manual inspection for exceptional eGFR values were excluded. This 
resulted in 223 individuals with fast progression (first and parts of second quintile, 
median eGFR slope of -6.75 mL/min/year) and 258 individuals with stable course 
(fourth quintile, median eGFR slope of 0.1 mL/min/year) who were selected for this 
study. Further details of the cohort derivation may be found in Supplement section 1 
and in (9).  
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Outcome of Interest 
The study outcome was an individuals’ course of renal function decline as 
determined by eGFR trajectory (fast progression versus stable course) where eGFR 
was computed according to the CKD-EPI equation (21). 
Clinical Risk Factors 
Clinical risk factors which were included in the analysis comprised age, sex, serum 
cholesterol, urine albumin-to-creatinine ratio, HbA1C, mean arterial pressure, BMI, 
smoking status and duration of type 2 diabetes at study entry. We also included 
eGFR at baseline as it was found to be an important covariate in our preceding 
analysis (9).  
Biomarker Selection and Measurement  
Baseline plasma samples were subjected to targeted proteomics and metabolomics 
profiling as well as untargeted lipidomics profiling. A complete list of all candidate 
biomarkers is provided in Supplement section 3. All markers were measured in K3 
EDTA plasma that was stored at -80°C immediately after collection. All samples were 
handled in an identical manner.  
Protein Biomarker Candidates 
Details on the protein biomarker selection can be found in a previous publication (6). 
Protein marker measurements and quality control data were also described previously 
(9). In short, the following 15 plasma markers were selected and analyzed in this 
current study: UMOD, Endostatin, CystatinC, MMP1, MMP7, CCL2, GH, VCAM1, 
HGF, CHI3L1, TIE2, TNFR1, KIM1, FGF23 and NTproBNP. SOST and MMP8 were 
initially also selected but subsequently excluded from all multivariable analyses due to 
measurement issues as reported previously in (9). 
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Metabolomics Biomarker Candidates 
Metabolomics analysis was performed using targeted hydrophilic interaction liquid 
chromatography coupled with tandem mass spectrometry (HILIC-LC-MS/MS) 
methodology. A detailed description of the metabolomics analysis may be found in 
Supplement section 3. In brief, metabolites were extracted from plasma samples 
using acetonitrile:isopropanol:water. HILIC separation was achieved using an apHera 
NH2 column (Supelco Analytical, Bellefonte, PA, USA) and LC-MS/MS analysis was 
carried out on a Shimadzu Nexera UPLC system (Shimadzu, Kyoto, Japan) coupled 
with a SCIEX Triple Quadrupole 6500+ mass spectrometer (SCIEX Framingham, 
MA, USA). 
Lipid Biomarker Candidates 
Mass spectrometry-based lipid analysis was performed at Lipotype GmbH using high 
throughput Shotgun Lipidomics (Dresden, Germany) technology as described in (22-
24).  A detailed description of the lipid extraction and measurement process may be 
found in Supplement section 3. In total 637 lipids from all 16 lipid classes could be 
identified. Out of these, 197 lipids that could be determined in more than 66% of 
samples were included in further statistical analysis in this study.  
Statistical Analysis 
We estimated the effects of clinical risk factors and biomarkers on the binary 
outcome (fast progression versus stable course) using Bayesian multivariable logistic 
regression models with shrinkage priors to identify important risk factors. The 
Bayesian framework was chosen as it allows incorporation of the a-priori known data 
structure with four groups of variables (clinical covariates, proteomics, metabolomics, 
lipidomics) and provided a conceptually clear way of handling missing data. 
Furthermore, uncertainty in estimated variable effects could be assessed by their 
posterior distributions. All biomarker values were log2 transformed to achieve 
17 
 
symmetric distributions. For comparability, all variables were centered and scaled to 
have zero mean and unit variance. Results are presented as standardized odds 
ratios (sOR), such that values larger than unity correspond to faster eGFR decline. 
We summarize posterior distributions by means and 95% BCI (defined by highest 
posterior density intervals), which are contiguous regions containing the quantity of 
interest with 95% probability, given the prior assumptions and the data. The ability to 
discriminate the two patient groups was expressed in terms of AUROC, which was 
estimated using 5 times repeated 5-fold cross-validation. 
We used shrinkage prior distributions based on the regularized horseshoe prior (25), 
which expressed our belief that only few biomarkers have a relevant individual 
association with the outcome. This prior specification shrank regression coefficients 
of weak predictors towards zero (corresponding to odds ratios of unity). 
Hyperparameters were specified following recommendations from the literature and 
were guided by model convergence (25-27). 
To investigate the added value of using biomarkers on top of clinical covariates we 
fitted “single group” and “structured” models. “Single group” models included only one 
group of variables (i.e. clinical variables or a single biomarker platform). “Structured” 
models included all variables with coefficient priors accommodating the grouping of 
the variables by slightly extending the definition of the horseshoe prior. We added an 
additional shrinkage parameter for each group, which allowed hierarchical attribution 
of shrinkage to groups of variables and to variables within a group. This was 
motivated by the careful preselection of the protein biomarkers, whereas the full 
metabolite and lipid biomarker panels were of a more explorative nature, therefore 
likely requiring stronger regularization. As sensitivity analysis, we also fitted 
“combined” models which contained all variables but ignored their grouped data 
structure and used standard regularized horsehoe priors, as well as models based on 
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unsupervised principal components computed from each group.  
Importance of predictors was assessed after model fit following methods outlined in 
(28; 29), which allowed computing predictions using only a subset of variables of a 
reference model. Using this technique, we obtained AUROC values corresponding to 
submodels of our presented reference models within the repeated cross-validation to 
investigate the change in discriminative accuracy when using only subsets of 
variables for predictions. Our simple strategy to choose these predictor subsets was 
to start with an intercept-only model, to which further variables were added in order of 
their absolute effect size (absolute posterior mean of the reference model). 
Uncertainty due to missing data was accounted for using 20 multiply imputed 
datasets, extending our approach from (9) to the novel metabolite and lipid 
biomarkers. The Bayesian framework allowed pooling of the posteriors resulting from 
the multiple imputed datasets into a single pooled posterior, incorporating the 
additional uncertainty due to missing data. The pooled posterior of each model was 
used for further summarization.  
Convergence of the Bayesian models was monitored using standard diagnostic tools 
(Supplementary Table S3). All analyses were implemented in R 3.4.1 (https://www.r-
project.org/foundation, Vienna, AT), using Stan 2.18.0 (30) for fitting the Bayesian 
models. The Stan implementation of our models can be found in Supplement 
sections 11 and 12, based on code published in (25). Statistical methodology is fully 
described in Supplement section 2. 
Sample Size Considerations 
The sample size considerations were reported previously and were initially based on 
identification of single markers in a cohort study (9). Regarding the power of the current 
study, a sample size of 209 cases and 209 controls was sufficient to detect a 
standardized odds ratio of 1.5 of a normally distributed biomarker (or biomarker score) 
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adjusted for other covariates with a power of 80% at a two-sided significance level of 
5%. This calculation further assumed that the biomarker exhibited a squared multiple 
correlation of 0.5 with the adjustment covariates. The power analysis was conducted 
using nQuery software version 8.2. 
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 Overall 
eGFR trajectory Baseline eGFR 
Stable Fast 
Above median 
(84 ml/min) 
Below or equal 
to median (84 
ml/min) 
Number of persons 481 258 223 240 241 
Age (Years) 64 ± 9.3 64 ± 10 65 ± 9 60 ± 8 68 ± 8 
Sex (Female) 232 (47%) 117 (45%) 115 (50%) 95 (40%) 133 (55%) 
Smoking status (Never) 250 (51%) 134 (52%) 116 (50%) 100 (42%) 145 (60%) 
Duration of type 2 
diabetes (Years) 
10.8 ± 8.8 10 ± 8 12 ± 9 8 ± 7 13 ± 10 
BMI (kg/m2) 31 ± 5.5 31 ± 5 32 ± 6 32 ± 6 31 ± 5 
Systolic blood pressure 
(mmHg) 
138 ± 17.4 138 ± 16 139 ± 19 139 ± 18 138 ± 17 
Diastolic blood pressure 
(mmHg) 
79 ± 10.3 79 ± 10 79 ± 10 81 ± 10 77 ± 10 
HbA1c (mmol/mol) 51 (45 / 60) 51 (45 / 61) 51 (44 / 60) 51 (44 / 61) 52 (45 / 60) 
Hemoglobin (mmol/l) 8.6 (8.1 / 9.3) 8.8 (8.2 / 9.3) 8.5 (7.9 / 9.1) 8.9 (8.3 / 9.4) 8.4 (7.8 / 9.1) 
Serum glucose (mmol/l) 7.4 (6.2 / 9) 7.5 (6.3 / 9) 7.4 (6 / 8.9) 7.4 (6.2 / 9.1) 7.4 (6.1 / 8.9) 
Serum cholesterol 
(mmol/l) 
4.6 (4 / 5.5) 4.6 (4 / 5.4) 4.6 (4 / 5.6) 4.5 (3.9 / 5.4) 4.7 (4 / 5.4) 
Serum creatinine 
(µmol/l) 
77 (66 / 95) 77 (67 / 95) 77 (65 / 95) 95 (81 / 111) 67 (60 / 75) 
UACR* (mg/g) 8.8 (4.7 / 26.5) 8.2 (4.6 / 21) 9.2 (5 / 36.5) 7.6 (4.2 / 17.4) 10.8 (5.6 / 40.4) 
Glucose lowering 
agents† 
     
None 59 (12%) 35 (14%) 24 (11%) 38 (16%) 21 (9%) 
1 – 2 agents 355 (74%) 192 (74%) 163 (73%) 175 (73%) 180 (75%) 
> 2 agents 67 (14%) 31 (12%) 36 (16%) 27 (11%) 40 (16%) 
Blood pressure lowering 
agents‡ 
     
None 77 (16%) 52 (20%) 25 (11%) 59 (25%) 18 (7%) 
1 – 2 agents  195 (41%) 106 (41%) 89 (40%) 111 (46%) 84 (35%) 
> 2 agents 209 (43%) 100 (39%) 109 (49%) 70 (29%) 139 (58%) 
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 Overall 
eGFR trajectory Baseline eGFR 
Stable Fast 
Above median 
(84 ml/min) 
Below or equal 
to median (84 
ml/min) 
ESA therapy§ 11 (2%) 4 (2%) 7 (3%) 0 (0%) 11 (5%) 
eGFR CKD-EPI 
(ml/min/1.73m2) 
84 (64 / 94) 85 (65 / 96) 82 (63 / 94) 94 (90 / 100) 64 (50 / 74) 
eGFR CKD-EPI decline 
per year 
(ml/min/1.73m2/year) 
-0.7 (-6.3 / 
0.2) 
0.1 (-0.4 / 0.7) -6.8 (-9 / -5.5) -0.7 (-6.7 / 0) -0.7 (-6 / 0.4) 
Follow-up (months) 35 35 34 34 35 
 
*UACR: Urine albumin-to-creatinine ratio 
† Agent classes: Biguanides, Insulin, Sulfonylureas, DPPIV inhibitors/GLP1 agonists, 
Glinides, Glitazones, Alpha-Glucosidase-inhibitors, SGLT2 
‡ Agent classes: ACE inhibitors / ARBs, β-blockers, Calcium antagonists (including 
direct vasodilators), α-blockers, Diuretics (Thiazide diuretics / Loop diuretics) 
§ Including Darbepoetin alfa, Epoetin alfa, Epoetin beta, Epoetin theta, Epoetin zeta, 
Others 
Table 1. Cohort characteristics 
Characteristics of the study cohort, overall and stratified by pre-defined eGFR 
trajectory as well as by baseline eGFR. This table presents the same data as Table 1 
in (9), which found baseline eGFR to be important for prediction of future eGFR 
trajectories. For baseline eGFR we chose the median of the cohort (84 
ml/min/1.73m2) as threshold to accommodate the early disease stage of the 
individuals. Data are reported as mean ± standard deviation, median (1st quartile, 3rd 
quartile) and absolute frequency (relative frequency). Clinical data was almost 
completely available (number of missing values: HbA1C 4, hemoglobin 9, serum 
glucose 1, serum cholesterol 1, urine albumin-to-creatinine ratio 14).   
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Model 
AUROC 
Mean Median 95% BCI 
Clinical 0.55 0.55 0.46 0.64 
Clinical with Shrinkage 0.55 0.54 0.46 0.64 
Proteomics 0.63 0.64 0.51 0.76 
Metabolomics 0.58 0.58 0.47 0.69 
Lipidomics 0.54 0.54 0.46 0.63 
Main Structured 0.63 0.64 0.53 0.74 
 
Table 2. Model discrimination of fast progressing versus stable individuals  
Discrimination of eGFR trajectory groups (fast progression versus stable course) with 
the presented models. Performance is measured in terms of cross-validated area 
under the receiver operatic characteristic curve (AUROC) and presented by posterior 
means, medians and 95% Bayesian credible interval (BCI). “Main Structured” 
indicates the main model of the study, using all variables with a prior adapted to the 
group structure of the data.  
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Figure 1. Standardized odds ratios from the main structured model  
Coefficient posteriors from the main structured model including 402 candidate 
predictors and priors reflecting the group structure of the variables. The top 15 
predictors in terms of effect size (absolute marginal posterior mean) are shown. Circles 
depict a point estimate (posterior mean), the posterior median is indicated by a vertical 
bar. The thick line represents the interquartile range and the thin line a 95% Bayesian 
credible interval. DM2 denotes type 2 diabetes mellitus. Group assignments are 
indicated by superscript initials (C for Clinical, P for Proteomics, M for Metabolomics, 
L for Lipidomics). Exact values for the standardized odds ratios are given in 
Supplementary Table S2. 
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Figure 2. Change in model performance when using a limited number of 
predictors in the main structured model 
Change in model performance when only a limited number of predictors is used to 
discriminate eGFR trajectory groups. Circles depict a point estimate of the cross-
validated AUROC (posterior mean), the posterior median is indicated by a horizontal 
bar. The thick line represents the interquartile range and the thin line a 95% Bayesian 
credible interval. The horizontal dashed line indicates the AUROC of the main 
structured model using all 402 variables, which serves as a reference. Modelsize 
denotes the number of variables in the model, starting with the intercept-only model, 
then adding variables in order of their effect size as shown in Figure 1 (starting at the 
top with baseline eGFR). The predictions of the reference model were than projected 
onto the corresponding subset of its variables via the methodology outlined in the 
Statistical Methods section in order to obtain the AUROC values depicted. 
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Cohort Selection and Grouping  
In this paragraph we add some further insight into the rationale behind our definition 
of the eGFR trajectory groups, which was motivated by our choice to use an 
accelerated case-control study. As described in the main manuscript and 
summarized by the flowchart below, we selected 223 fast progressing and 258 stable 
individuals from the full PROVALID cohort. This selection was based on the quintiles 
of estimated annual eGFR slopes. After screening for individuals for whom the eGFR 
slopes were unsteady (i.e. likely to be uninformative of their true disease status) and 
excluding them from the study, the remaining individuals from the first slope quintile (-
24.9 to -5.2 mL/min/year change of eGFR) represented the fast progressing group. 
These were complemented by persons from the second quintile (-5.2 to -2.6 
mL/min/year) in order to balance out the fraction of patients in advanced disease 
stages to mitigate selection bias (KDIGO stage G3a/b at baseline), which would 
otherwise have been underrepresented in the fast-progression sample. The stable 
individuals were the individuals from the fourth quintile (-0.8 to 1.4 mL/min/year). We 
chose to use the fourth quintile instead of the fifth as the latter represented persons 
with atypical eGFR trajectories, i.e. mostly later stage individuals (according to 
KDIGO stage at baseline) who were e.g. influenced by treatment changes which led 
to a slight recovery of their eGFR values and thus increasing eGFR slopes. 
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Supplementary Figure S2: Flowchart of study cohort selection from the PROVALID study (S1) 
Flowchart of study cohort selection from the PROVALID study, as previously reported in (S1). The full PROVALID 
cohort recruited persons in five countries, of which only three were available for the current analysis. The outcome 
groups were based on manual and statistical aspects to provide steady eGFR trajectories. Detailed information 
were previously reported in Supplementary Figure 1 and Supplementary Table 2 of (S1). 
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Supplementary Figure S3: eGFR trajectories of individuals selected for this study 
Each individual is represented in the above plot by a line, actual eGFR measurements are indicated as dots. The 
purpose of this graphic is to give an indication of the difference between the two selected groups of persons and 
on the general steadiness of their eGFR slopes. 
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Extended Statistical Methods 
We estimated the effects of clinical risk factors and biomarkers on the binary outcome (fast 
progression versus stable course) using Bayesian multivariable logistic regression models with 
shrinkage priors to identify important risk factors. Odds ratios larger than unity correspond to 
faster eGFR decline. Cohort characteristics are described by mean and standard deviation or 
median and first and third quartile for continuous variables or by frequency and percentage for 
categorical variables. 
Bayesian Framework 
The reason why we decided to model the data in a Bayesian framework were three-fold: first, 
to deal with missing data in a conceptually sound and practical way. Second, we could 
incorporate a-priori known information into the modelling approach. Specifically, this allowed 
us to adapt the models to the structure of our data, which comprised different groups of 
variables (clinical data, proteomics, metabolomics, lipidomics). Lastly, posterior distributions 
and credible intervals provided insights regarding the uncertainty of coefficient estimates and 
model performance results. Furthermore, we are able to report the models in a fully transparent 
manner (see code for the implementation of our analysis in Supplement sections 11 and 12).  
Alternative commonly used techniques such as the Lasso, Elastic net and other penalized 
regression approaches (adaptive Lasso, IPF Lasso) were considered but found to be lacking 
regarding the ability to provide interval estimates, had issues with available software or were 
more difficult to handle within the multiple imputation setup. 
The Bayesian framework required several decisions to be made before fitting the models, 
namely specifying the prior distributions for the model parameters. These priors are then 
combined with the data to yield posterior distributions, which correspond to the probability of 
the parameters given the data observed and the prior assumptions. The resulting coefficient 
posterior distributions were transformed to the odds ratio scale and summarised by their means 
and 95% highest posterior density intervals, which we call Bayesian credible interval (BCI) 
from now on. Point estimates (means) admit the usual interpretation as in a frequentist 
analysis: the expected increase in the odds of being classified as a fast progressing individual 
per unit (standard deviation in this work) of the corresponding variable. Credible intervals with 
95% coverage represent a contiguous region which contain the unobserved, true value of 
interest with at least 95% probability, given the model structure, prior assumptions and the 
data. They result in a more fine grained evaluation of uncertainty compared to confidence 
intervals due to the associated posterior distribution of the quantity of interest. While 
confidence intervals only yield the information whether a specific value is contained or not, the 
allocation of posterior probability mass allows to study how likely a specific value actually is. 
Predictions in this framework can be obtained using the coefficient posteriors and yield a 
distribution of predictions for each observation. 
Model Structures 
As a baseline for subsequent evaluation of more elaborate models, we fitted a clinical model 
using weakly informative Student-t prior distributions, which corresponded to a standard 
frequentist analysis of the data (see Supplementary Table S1 in Supplement section 4). 
To elucidate the added benefit of using biomarker on top of clinical covariates, we present 
several further types of models, differing by the variables contained and the prior choices. 
First, models which included only one group of variables (single group models). This allowed 
comparisons between the clinical covariates and the individual biomarker platforms. Second, 
domain knowledge inspired models which included all variables and had coefficient priors 
adapted to the structure of the data (structured models). Third, models which contained all of 
the variables (combined models) but with similar prior choices as the single group models, 
which were uninformed about the structure of the data. Lastly, models which were based on 
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principal components (PCA) in order to make the number of variables in each group equal. 
The last two model types served mainly as sensitivity analysis and are reported in 
Supplement sections 7 and 8. 
To make the effects of the variables comparable, we log2 transformed all of the biomarkers 
to achieve symmetric distributions and then centered and scaled all of the candidate 
predictors (including clinical) to have zero mean and unit variance. Hence, all odds ratios are 
to be interpreted in units of standard deviations and are denoted as standardized odds ratios 
(sOR). 
In contrast to the mixed model approach of our previous analysis on a subset of the data 
(S1) we decided to use logistic regression in the current setting. The main reason for that 
was the large number of covariates, which made the computational cost and complexity of 
mixed model inference infeasible. Furthermore, by resorting to a logistic regression we could 
focus on the association with the eGFR trajectories, which are less influenced by baseline 
eGFR values. Lastly, we could avoid the re-estimation of possibly unstable eGFR slopes and 
make use of the carefully established individual eGFR trajectory classification.  
 
Choice of Priors 
The choice of priors expressed our belief that only few biomarkers have a relevant individual 
association with the outcome of interest. This sparsity assumption was crucial in the setting of 
our current analysis, as we had more variables than “events” (i.e. the size of the smaller person 
group) – hence, some form of prior information was necessary to make the estimation of odds 
ratios robust. This was achieved by the use of coefficient priors which induced shrinkage or 
regularization of coefficient estimates towards zero (corresponding to an odds ratio of unity).  
Our main analyses were based on regularized horseshoe prior distributions (S2). These so 
called global local shrinkage priors assign a normal distribution to each of the coefficients, 
centered around zero and with a variance depending on the data. The variance parameter 
consists of two parts: a global parameter 𝜏 that shrinks all of the predictor effects towards zero 
and a local parameter 𝜆𝑖 which allows certain variables to escape this global shrinkage. This 
prior was used by the single group, combined and PCA-based models. Each coefficient 𝛽𝑖, for 
all variables numbered from 1 to 𝑝, were assigned the same prior defined by 
𝛽𝑖~𝑁 (0, 𝜏
2𝜆?̃?
2
) , 𝜆?̃?
2
=
𝑐2𝜆𝑖
2
𝑐2 + 𝜏2𝜆𝑖
2 , 
𝜆𝑖~𝑆𝑡𝑢𝑑𝑒𝑛𝑡 − 𝑡𝜈
+(0, 𝑠𝜆
2), 
𝑐2 ~ 𝑖𝑛𝑣 − 𝑔𝑎𝑚𝑚𝑎(𝑎, 𝑏), 
𝜏2~𝑆𝑡𝑢𝑑𝑒𝑛𝑡 − 𝑡1
+(0, 𝑠𝜏
2) 
Here 𝑆𝑡𝑢𝑑𝑒𝑛𝑡 − 𝑡𝜈
+ denotes a half Student-t distribution with degrees of freedom 𝜈. Several 
hyperparameters needed to be defined to complete the specification. For the global scale 𝜏 we 
followed the recommendations in (S3) and set 𝑠𝜏 = 1 (note that in that case the assumed half-
Student-t prior distribution is equal to the half-Cauchy distribution as found in the literature). 
For the local scale 𝜆𝑖, we set 𝑠𝜆 = 1 and 𝜈 = 3, the latter was done to improve convergence 
properties and speed of the Marko chain Monte Carlo (MCMC) sampling while having virtually 
no impact on predictive abilities. For the auxiliary parameter 𝑐, we set 𝑎 = 𝑏 = 3, again to 
improve sampling robustness. Alternative prior parameter settings were based on 
considerations in (S2) and are reported as sensitivity analysis (Supplement section 0). 
The structured models used a different shrinkage prior, which was similar to the approach 
presented in (S4). We added a further layer of shrinkage parameters between the global and 
local scale. It corresponds to a group scaling, as it is dependent on the group to which the 
predictor belongs to.  
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Hence, we defined  
𝛽𝑖~𝑁 (0, 𝜏
2𝜏𝐺𝑖
2 𝜆?̃?
2
) , 𝜆?̃?
2
=
𝑐2𝜆𝑖
2
𝑐2 + 𝜏2𝜏𝐺𝑖
2 𝜆𝑖
2 , 
𝜏𝐺
2~𝑆𝑡𝑢𝑑𝑒𝑛𝑡 − 𝑡1
+(0, 𝑠𝜏
2),   
Where 𝐺 represents the variable group (i.e. clinical, proteomics, metabolomics or lipidomics) 
and 𝐺𝑖 denotes the group to which predictor 𝑖 belongs to. The additional parameters for the 
group scale were set in the same way as for the global scale. This middle layer of shrinkage 
acts similar to “just another global” scale that modulates the overall shrinkage strength per 
group. The motivation was that we expected that discriminative power differs between the 
variable groups. The protein biomarkers were already selected in earlier studies and targeted 
at predicting the disease outcome, while the metabolomics and lipidomics did not undergo 
such a thorough selection process. Thus, they likely required stronger regularization to 
identify a small number of strong predictors. This idea is similar to the way IPF Lasso 
introduces modifiers for penalty factors depending on variable modality. The remaining 
hyperparameters were set as in the unstructured models. 
The base clinical model without regularization used weakly informative Student-t priors with 3 
degrees of freedom as priors, based on suggestions made in (S5). Its agreement with a 
frequentist analysis of the data is shown in   
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Supplementary Table S1 in Supplement section 4. 
Model Performance 
The ability to discriminate the two eGFR trajectory groups is expressed in terms of area under 
the receiver operating curve (AUROC), which was corrected for optimism using 5 times 
repeated 5-fold cross-validation. We approximated the full AUROC posterior distribution by 
doing 100 simulations from the posterior predictive densities for each fold in the repeated 
cross-validation. 
Identification of Important Predictors 
The drawback of using a Bayesian approach is that even though shrinkage priors shrink 
variable effects towards zero, they do not automatically select variables to produce truly sparse 
models, as the probability for a variable to have a coefficient larger than zero is always non-
zero. Thus, to identify a smaller number of biomarkers which are important to discriminate 
between fast progressing and stable individuals, we elucidated the performance of smaller 
models as a subsequent step. We followed a projection approach, based on the methodology 
outlined in (S6; S7). In this feature selection step, the initial model fitted on all variables served 
as a reference model. A submodel is a model that contains only a subset of the variables of 
the full model. The goal was then to search for submodels whose predictive ability was as good 
as the reference model. A very simple search strategy was to define submodels by including 
variables ranked by their absolute marginal effect strength (absolute value of mean of 
coefficient posterior). The coefficient posteriors for this submodel were then obtained from a 
linear regression where the linear predictors of the reference model served as outcome and 
only the specified subset of variables entered the model as independent variables. This 
essentially corresponds to a projection of the predictions from the full model to the restricted 
parameter space of the submodel, and thus only includes a subset of the variables. We 
computed the AUROC for submodels up to size 16 (i.e. starting with the intercept only model 
up to including the top 15 predictors) in the cross-validation to identify how the discriminative 
accuracy changes when making predictions using only the projected posteriors of the strongest 
predictors. More sophisticated search strategies to identify submodels were considered and 
tested, but lead to similar conclusions, as we were only interested in the change of AUROC in 
the submodels and not their exact constitution. Furthermore, the generally low AUROC values 
and clear results regarding predictor importance were further reasons for the similar results 
concerning the first few predictors, regardless of method used. Thus, and because of the 
simplicity of the approach which can be easily reported, we present the “naïve” approach of 
ranking by marginal effects here. 
Multiple Imputation 
As reported in Table 1 and the availability breakdown in Supplement section 3, several of the 
predictors had missing data issues, especially the lipidomics data. Therefore we extended our 
multiple imputation procedure from (S1) to also include the novel metabolomics and lipidomics 
biomarkers. Multiple imputation was conducted using multivariate imputation by chained 
equations, as implemented in the package “mice” for the R statistical software.  
The imputation model included all candidate predictors as well as the outcome eGFR and 
eGFR slope to impute the data. The outcome variable itself was completely available. Since 
measurements of biomarkers out of quantifiable range were set to suitable values prior to this 
imputation procedure, we assumed the remaining data was missing at random. We chose to 
use 20 imputed datasets as a compromise between computational effort and statistical 
accuracy. Convergence of the multiple imputation procedure was checked using graphical 
methods provided by the “mice” package and found to be satisfactory. 
The Bayesian framework admits to incorporate the multiple imputed datasets naturally by 
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pooling the posteriors from models fitted to each imputed dataset. Thus, we obtained a final 
model which incorporates uncertainty due to missing data into the posterior. This model could 
then be used for further analysis.  
We decided not to incorporate the imputation model into the Bayesian logistic models 
themselves for three reasons: first, we use the same imputed data for several model structures. 
This ensured comparability. Second, the computational effort required to impute the data in 
each model individually would have been prohibitive. Lastly, the model complexity would have 
increased, making it more difficult to sample robustly from these models. 
Sensitivity Analysis for Prior Parameters 
The sensitivity to the prior assumptions were thoroughly investigated. We found the results for 
the strong predictors to be very robust. Our choice of hyperparameters was guided mostly by 
recommendations in the literature and prior knowledge gained in (S1). We checked model 
robustness and aimed at preventing sampling issues as reported by the sampler diagnostics 
implemented in Stan (namely divergent transitions) as well as traditional MCMC diagnostics 
(?̂? statistics, ratio of effective samples and total posterior samples).  
Software and Code Used 
Our analysis was implemented in R 3.4.1 (https://www.r-project.org/foundation, Vienna, AT), 
using Stan 2.18.0 (S8) for fitting the Bayesian models. The code to run our analysis for logistic 
regression models using regularized horseshoe priors can be found in Supplement section 11. 
Our implementation of the structured horseshoe models can be found in Supplement section 
12. The code was based on the implementation examples in (S2).  
Markov chain Monte Carlo Sampling 
We used the NUTS algorithm of the Stan software package, accessed via the R interface rstan, 
to draw samples from the posterior distributions of our models. Each model for each imputed 
dataset used 3 chains for parallel sampling. We used 2000 warmup and 1000 sampling 
iterations. For the main tuning parameter adapt_delta we used a value of 0.9 to prevent issues 
during model sampling when using the regularized horseshoe priors, even if lower settings 
also led to robust sampling in most cases. Other settings were left at their default values.  
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Biomarker Measurement and Data Overview 
Detailed Metabolomics Measurement Procedure 
Metabolomics analysis was performed using targeted hydrophilic interaction liquid 
chromatography coupled with tandem mass spectrometry (HILIC-LC-MS/MS) methodology. 
Plasma samples were thawed on ice, after which 300 µL of a pre-chilled mixture of 
acetonitrile:isopropanol:water (3:3:2 v/v) was added to 50 µL of each plasma sample. The 
samples were mixed thoroughly and incubated at -20°C overnight. The samples were then 
centrifuged for 15 min at 3200 x g at 4°C, and the supernatants were removed for LC-MS/MS 
analysis. A pooled QC sample was created by taking an aliquot of the same volume from all 
the extracted samples in the study.  This pooled sample was then serially diluted to form a 
standard curve.  The study samples were then further diluted 1:1 with the same pre-chilled 
acetonitrile:isopropanol:water mixture prior to analysis. 
LC-MS/MS was performed using a Shimadzu Nexera UPLC system (Shimadzu, Kyoto, 
Japan) coupled with a SCIEX Triple Quadrupole 6500+ mass spectrometer (SCIEX 
Framingham, MA, USA). HILIC-LC separation was achieved using an apHera NH2 column 
(15cm × 2mm, 5 µm particle size, Supelco Analytical, Bellefonte, PA, USA) with an apHera 
NH2 guard column (1cm × 2 mm, 5 µm particle size, Supelco Analytical, Bellefonte, PA, 
USA).  The mobile phases were 50 mM ammonium bicarbonate (pH 9.5, adjusted with 
ammonium hydroxide) (A) and acetonitrile (B). After a 3-min isocratic run at 90% B, gradients 
to 85%, 75%, 45%, 30% and 2% B were concluded at 3, 11.5, 15, 20 and 21 min, 
respectively. A gradient to 90% B was completed at 23.5 min and was followed by a 4-min 
column equilibration. The flow rate started at 0.25 mL/min and increased to 0.35 mL/min at 
20 min and 0.4 mL/min at 21 min and then went back to 0.25 mL/min at the end of the 
equilibration.  
Positive and negative scheduled MRM transitions were monitored for a total of 215 
metabolites.  The metabolite peaks were integrated, and the AUCs and relative intensities of 
the metabolites were calculated using SCIEX MultiQuant 3.0.2 software (SCIEX 
Framingham, MA, USA). 
Detailed Lipidomics Measurement Procedure 
Mass spectrometry-based lipid analysis was performed at Lipotype GmbH using high 
throughput Shotgun Lipidomics (Dresden, Germany) technology as described in (S9). 
Samples were processed in batches of 84 samples and each batch was accompanied by 
identical reference samples and blank controls. Lipids were extracted from an equivalent of 1 
µL of undiluted plasma using methyl tert-butyl ether/methanol (7:2, V:V) as in (S10). Known 
amounts of internal standards were pre-mixed with the organic solvent mixture. All extraction 
steps were carried out on the Hamilton Robotics STARlet robotic platform with the Anti 
Droplet Control feature for organic solvents pipetting.  
Samples were analyzed by direct infusion in a QExactive mass spectrometer (Thermo 
Scientific) equipped with a TriVersa NanoMate ion source (Advion Biosciences). Lipid 
identification and quantification from unprocessed mass spectra data was carried out using 
Lipotype’s proprietary LipotypeXplorer (S11). For quantification lipid intensities were 
normalized to lipid-class specific standards. Only lipids at least five-times higher than in blank 
samples were kept for measurement samples. Correction for batch-effects and analytical drift 
was performed using the reference samples. 
Analysis of reference samples verified high analytical quality and reproducibility. The median 
coefficient of variation across all classes and batches was 10.8%. 
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Biomarker Measurement Availability 
Availability for protein marker measurements is reported in more detail in the Supplement of 
(1). In summary, each protein biomarker was available for at least 90% of the participants; 12 
out of 15 markers were available for at least 95% of the participants. 
Each metabolite biomarker was available for at least 98% of participants. 
For lipid biomarkers the number of missing measurements was higher. We selected 197 out 
of 637 lipid markers for which at least 66% of participants had measurements available. This 
threshold is similar to other studies in the field. It presents a compromise between using as 
many markers as possible while providing the multiple imputation procedure with enough 
information for stable results and convergence. The amount of missing data was comparable 
between the eGFR trajectory groups.  
Biomarker lists 
The following lists give the names of all biomarker candidates used in the current analysis. 
Proteomics (15 biomarkers) 
CystatinC MMP7 
Endostatin TIE2 
UMOD TNFR1 
CCL2 VCAM1 
CHI3L1 KIM1 
GH FGF23 
HGF NTproBNP 
MMP1  
 
Metabolomics (180 biomarkers) 
1-Methyladenosine C3+O Carnitine Kynurenic Acid 
1-Methyl-Histidine C4 Carnitine Kynurenine 
2,3-Dihydroxybenzoic Acid C5:0 C4+O Carnitine Lactate 
2-Aminobutyrate 58 C5:1 Carnitine Leucine 
2-Aminooctanoic Acid C5 Sa 89 Lpc 16:0 
2-Hydroxybutyric Acid C5+0 Carnitine Lysine 
2-Isopropylmalic Acid C6:0 Carnitine Malate 
3-Hydoxy-Dl-Kynurenine 
162 
C6:0+O Carnitine Methionine 
3-Hydroxybutyric Acid C6:1 Carnitine Methionine Sulfoxide 
3-Phosphoglycerate C6:1+O Carnitine Methylnicotinamide 
4-Pyridoxic Acid C6 Sa 89 Mevalonic Acid 59.1 
6-Phospho-D-Glucono-1,5-
Lactone 
C7:0+O Carnitine Myo-Inositol 
7-Methylguanosine C8:0 Carnitine N-Acetyl-Dl-Serine 
Acetoacetate C8:0+O Carnitine N-Acetyl-Glutamine 
Acetylcarnitine Dl C8:1 Carnitine N-Acetyl-L-Alanine 
Acetyllysine C8:1+O Carnitine Nadp+ Pos 
Acetylphosphate Carnitine Nadph 
Adenine Cdp N-Carbamoyl-L-Aspartate 
Neg 
Adp Chenodeoxycholate N-Formyl Kynurenine 146 
A-Ketoglutarate Cholesteryl Sulfate Ng,Ng-Dimethyl-L-Arginine 
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Alanine Choline Nicotinamide 
Allantoate Citrulline O-Acetyl-L-Serine 
Allantoin Creatine Octulose-1,8-Bisphosphate 
(Obp) 
Aminoadipic Acid Creatinine O-Phosphorylethanolamine 
Amp Cyclic Bis(3->5) Dimeric 
Gmp 
Ornithine 
Arginine Cyclic-Amp Orotate 
Asparagine Cysteine Pantothenate 
Aspartate Cystine Phenylalanine 
Betaine Datp Phenyllactic Acid 
Betaine Aldehyde Dctp Phenylpropiolic Acid 
C0 Carnitine Deoxyribose-Phosphate Phosphoenolpyruvate 
C10:0 Carnitine D-Glucarate Phosphorylcholine 
C10:0+O Carnitine D-Gluconate P-Hydroxybenzoate 
C10:1 Carnitine D-Glucosamine-6-
Phosphate 
Proline 
C10:2 Carnitine D-Glyceraldehdye-3-
Phosphate 
Purine 
C10:3 Carnitine Dimethylglycine Pyroglutamic Acid 
C12:0 Carnitine Dl-3-Aminobutyrate Riboflavin 
C12:1 Carnitine Dl-Pipecolic Acid Ribose-Phosphate 
C12:1+O Carnitine Dttp S1p 
C14:0 Carnitine Erythritol 89 S1p-Neg 
C14:0+O Carnitine Ethanolamine Sarcosine 
C14:1 Carnitine Glutamate Serine 
C14:2 Carnitine Glutamine Shikimate 
C16:0 Carnitine Glutathione Neg Shikimate-3-Phosphate 
C16:0+O Carnitine Glycerate Succinate 
C16:1 Carnitine Glycerophosphocholine Taurine 
C16:1+O C17:0 Carnitine Glycine Taurodeoxycholate 
C18:0 Carnitine Glycolate Tetradecanedioic Acid 239 
C18:0+O Carnitine Guanidoacetic Acid Threonine 
C18:1 Carnitine Guanine Trans, Trans-Farnesyl 
Diphosphate 
C18:1+O Carnitine Histidine Tryptophan 
C18:2 Carnitine Hydroxyisocaproic Acid Tyrosine 
C18:3 Carnitine Hydroxyproline Uracil 
C2 Carnitine Hypoxanthine Urea 
C2+O Carnitine Imidazoleacetic Acid Uric Acid 
C20:0 Carnitine Indole Valine 
C20:0+O Carnitine Indole-3-Carboxylic Acid Xanthine 
C20:3 Carnitine Indoleacrylic Acid Xanthosine 
C20:4 Carnitine Inosine Xanthurenic Acid 
C3 Carnitine Isoleucine Ztp 78.9 
 
Lipidomics (197 biomarkers) 
CE 14:0;0 PC 16:1;0_18:1;0 PE O-16:1;0/20:3;0 
CE 15:0;0 PC 16:1;0_18:2;0 PE O-16:1;0/20:4;0 
CE 16:0;0 PC 16:1;0_20:4;0 PE O-16:1;0/22:5;0 
CE 16:1;0 PC 17:0;0_18:1;0 PE O-18:1;0/18:2;0 
CE 17:0;0 PC 17:0;0_18:2;0 PE O-18:1;0/20:4;0 
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CE 17:1;0 PC 17:0;0_20:3;0 PE O-18:2;0/18:1;0 
CE 18:0;0 PC 17:0;0_20:4;0 PE O-18:2;0/18:2;0 
CE 18:1;0 PC 18:0;0_18:1;0 PE O-18:2;0/20:4;0 
CE 18:2;0 PC 18:0;0_18:2;0 PI 16:0;0_18:1;0 
CE 18:3;0 PC 18:0;0_18:3;0 PI 16:0;0_18:2;0 
CE 19:2;0 PC 18:0;0_20:2;0 PI 16:0;0_20:3;0 
CE 20:1;0 PC 18:0;0_20:3;0 PI 16:0;0_20:4;0 
CE 20:2;0 PC 18:0;0_20:4;0 PI 18:0;0_18:1;0 
CE 20:3;0 PC 18:0;0_20:5;0 PI 18:0;0_18:2;0 
CE 20:4;0 PC 18:0;0_22:4;0 PI 18:0;0_20:3;0 
CE 20:5;0 PC 18:0;0_22:5;0 PI 18:0;0_20:4;0 
CE 22:6;0 PC 18:0;0_22:6;0 PI 18:1;0_18:1;0 
CE 23:2;0 PC 18:1;0_18:1;0 PI 18:1;0_18:2;0 
CE 24:1;0 PC 18:1;0_18:2;0 PI 18:1;0_20:4;0 
CE 24:2;0 PC 18:1;0_20:2;0 PI 18:2;0_18:2;0 
Cer 40:1;2 PC 18:1;0_20:3;0 SM 32:1;2 
Cer 40:2;2 PC 18:1;0_20:4;0 SM 34:1;2 
Cer 42:1;2 PC 18:2;0_18:2;0 SM 34:2;2 
Cer 42:2;2 PC 18:2;0_20:1;0 SM 36:1;2 
Chol PC 18:2;0_20:3;0 SM 36:2;2 
DAG 16:0;0_18:1;0 PC 18:2;0_20:4;0 SM 38:2;2 
DAG 16:0;0_18:2;0 PC O-16:0;0/16:0;0 SM 40:1;2 
DAG 16:1;0_18:1;0 PC O-16:0;0/16:1;0 SM 40:2;2 
DAG 18:1;0_18:1;0 PC O-16:0;0/18:1;0 SM 42:2;2 
DAG 18:1;0_18:2;0 PC O-16:0;0/18:2;0 TAG 46:0;0 
DAG 18:1;0_18:3;0 PC O-16:0;0/20:3;0 TAG 46:1;0 
DAG 18:2;0_18:2;0 PC O-16:0;0/20:4;0 TAG 46:2;0 
LPC 16:0;0 PC O-16:0;0/22:4;0 TAG 48:0;0 
LPC 16:1;0 PC O-16:0;0/22:5;0 TAG 48:1;0 
LPC 18:0;0 PC O-16:1;0/16:0;0 TAG 48:2;0 
LPC 18:1;0 PC O-16:1;0/18:0;0 TAG 48:3;0 
LPC 18:2;0 PC O-16:1;0/18:1;0 TAG 49:1;0 
LPC 20:3;0 PC O-16:1;0/18:2;0 TAG 49:2;0 
LPC 20:4;0 PC O-16:1;0/20:3;0 TAG 50:1;0 
LPE 16:0;0 PC O-16:1;0/20:4;0 TAG 50:2;0 
LPE 18:0;0 PC O-16:2;0/18:0;0 TAG 50:3;0 
LPE 18:1;0 PC O-16:2;0/18:1;0 TAG 50:4;0 
LPE 18:2;0 PC O-17:0;0/15:0;0 TAG 51:1;0 
LPE 20:4;0 PC O-17:0;0/17:1;0 TAG 51:2;0 
LPE 22:6;0 PC O-17:2;0/17:0;0 TAG 51:3;0 
PC 14:0;0_16:0;0 PC O-18:0;0/14:0;0 TAG 52:2;0 
PC 14:0;0_18:1;0 PC O-18:0;0/16:1;0 TAG 52:3;0 
PC 14:0;0_18:2;0 PC O-18:0;0/20:4;0 TAG 52:4;0 
PC 15:0;0_18:1;0 PC O-18:1;0/16:0;0 TAG 52:5;0 
PC 15:0;0_18:2;0 PC O-18:1;0/18:2;0 TAG 52:6;0 
PC 16:0;0_16:0;0 PC O-18:1;0/20:3;0 TAG 53:2;0 
PC 16:0;0_16:1;0 PC O-18:1;0/20:4;0 TAG 53:3;0 
PC 16:0;0_17:1;0 PC O-18:2;0/16:0;0 TAG 53:4;0 
PC 16:0;0_18:0;0 PC O-18:2;0/18:1;0 TAG 54:3;0 
PC 16:0;0_18:1;0 PC O-18:2;0/18:2;0 TAG 54:4;0 
PC 16:0;0_18:2;0 PC O-18:2;0/20:4;0 TAG 54:5;0 
PC 16:0;0_18:3;0 PE 16:0;0_18:1;0 TAG 54:6;0 
PC 16:0;0_20:1;0 PE 16:0;0_18:2;0 TAG 54:7;0 
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PC 16:0;0_20:2;0 PE 16:0;0_20:4;0 TAG 56:3;0 
PC 16:0;0_20:3;0 PE 18:0;0_18:1;0 TAG 56:4;0 
PC 16:0;0_20:4;0 PE 18:0;0_18:2;0 TAG 56:5;0 
PC 16:0;0_20:5;0 PE 18:0;0_20:4;0 TAG 56:6;0 
PC 16:0;0_22:4;0 PE 18:1;0_18:1;0 TAG 56:7;0 
PC 16:0;0_22:5;0 PE 18:1;0_18:2;0 TAG 56:8;0 
PC 16:0;0_22:6;0 PE 18:1;0_20:4;0 TAG 58:8;0 
PC 16:1;0_18:0;0 PE O-16:1;0/18:2;0  
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Correlation Structure 
 
Supplementary Figure S4: Correlation matrix of all candidate predictors  
Correlation matrix with Spearman correlation coefficients for all variables. Variable groups are represented by 
blocks separated by black lines. The matrix comprises 10 clinical, 15 protein, 180 metabolite and 197 lipid 
variables, respectively. 
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Single Group Models 
This section includes the results for models comprising only a single group of variables. We 
report coefficients of the top 15 predictors in terms of absolute effect strength (absolute 
marginal posterior means). Model performance in terms of cross-validated AUROC is given 
in the main manuscript (Table 2).   
Clinical Model  
 
Supplementary Figure S5: Standardized odds ratios for the clinical model 
Coefficient posteriors for clinical model with weakly informative Student-t priors, equivalent to a frequentist 
analysis, ranked by marginal means. Point estimate is given by the mean (circle), the median is indicated by a 
vertical line. The thick horizontal line represents the interquartile range, while the thin line represents a 95% 
Bayesian credible interval. 
As a comparison to the Bayesian approach we also fitted frequentist logistic regression 
models to the multiple imputed datasets. Final coefficient estimates were pooled using 
Rubin’s rules.   
47 
 
Supplementary Table S1 shows that the two modelling approaches led to virtually identical 
results in this simple baseline case. 
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Supplementary Table S1: Standardized odds ratios for the clinical model (Frequentist and Bayes 
estimates) 
Standardized odds ratios (sOR) of progression for clinical risk factors. The Bayesian model used weakly 
informative Student-t priors and the reported odds ratio is the mean of the model posterior.  
Variable 
Frequentist Model Bayesian Model 
sOR 
95% Confidence 
interval sOR 
95% Bayesian 
credible interval 
Lower Upper Lower Upper 
Duration DM2 1.41 1.14 1.74 1.43 1.14 1.74 
Age 1.23 0.97 1.56 1.25 0.96 1.56 
BMI 1.21 0.99 1.47 1.22 0.98 1.46 
Baseline eGFR 1.18 0.93 1.5 1.2 0.92 1.49 
HbA1C 0.88 0.73 1.08 0.88 0.71 1.06 
Ever smoked 1.09 0.9 1.32 1.1 0.89 1.32 
Serum Cholesterol 1.09 0.9 1.32 1.1 0.89 1.31 
MAP 1.09 0.9 1.32 1.1 0.89 1.31 
UACR 1.08 0.89 1.31 1.08 0.87 1.3 
Sex (Male) 0.91 0.75 1.11 0.92 0.74 1.10 
 
Clinical Model with Shrinkage 
Supplementary Figure S6: Standardized odds ratios for the clinical model with shrinkage priors 
Coefficient posteriors for clinical model with shrinkage priors, ranked by marginal means. Point estimate is given 
by the mean (circle), the median is indicated by a vertical line. The thick horizontal line represents the interquartile 
range, while the thin line represents a 95% Bayesian credible interval. 
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Proteomics Model 
 
Supplementary Figure S7: Standardized odds ratios for the proteomics model 
Coefficient posteriors for proteomics model, ranked by marginal means. Point estimate is given by the mean 
(circle), the median is indicated by a vertical line. The thick horizontal line represents the interquartile range, while 
the thin line represents a 95% Bayesian credible interval. 
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Metabolomics Model 
 
Supplementary Figure S8: Standardized odds ratios for the metabolomics model 
Coefficient posteriors for the top 15 predictors of the metabolomics model, ranked by marginal means. Point 
estimate is given by the mean (circle), the median is indicated by a vertical line. The thick horizontal line 
represents the interquartile range, while the thin line represents a 95% Bayesian credible interval. 
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Lipidomics Model 
 
Supplementary Figure S9: Standardized odds ratios for the lipidomics model 
Coefficient posteriors for the top 15 predictors of the lipidomics model, ranked by marginal means. Point estimate 
is given by the mean (circle), the median is indicated by a vertical line. The thick horizontal line represents the 
interquartile range, while the thin line represents a 95% Bayesian credible interval.  
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Main Structured Model Coefficients 
Table with coefficient posteriors for the top 15 predictors from the main structured model 
(Figure 1 in main manuscript). 
Supplementary Table S2: Standardized odds ratios for the main structured model 
Summary of posteriors for standardized odds ratios of progression for top predictors of the main structured model. 
We report mean, median, quantiles and 95% Bayesian credible interval (BCI) of the model posterior. 
Variable Group Mean Median 
Quantiles 95% BCI 
25% 75% Lower Upper 
Baseline 
eGFR 
Clinical 
2.23 2.14 1.79 2.56 1 3.4 
KIM1 Proteomics 1.59 1.57 1.42 1.74 1.13 2.09 
NTproBNP Proteomics 1.28 1.26 1.13 1.41 0.97 1.65 
Duration 
DM2*  
Clinical 
1.25 1.24 1.11 1.37 0.97 1.61 
Kynurenine Metabolomics 1.14 1.04 1 1.21 0.94 1.61 
CystatinC Proteomics 1.13 1.06 1 1.2 0.87 1.53 
MMP1 Proteomics 1.1 1.07 1.01 1.16 0.93 1.35 
BMI Clinical 1.09 1.07 1.01 1.16 0.92 1.34 
Creatinine Metabolomics 1.09 1.02 1 1.09 0.92 1.49 
Sex (Male) Clinical 0.92 0.95 0.86 1 0.70 1.09 
HGF Proteomics 0.92 0.94 0.86 1 0.72 1.07 
MMP7 Proteomics 1.07 1.03 1 1.11 0.88 1.32 
Endostatin Proteomics 1.06 1.03 0.99 1.11 0.87 1.34 
Threonine Metabolomics 0.94 0.98 0.91 1 0.72 1.05 
C6:0+O 
Carnitine 
Metabolomics 1.06 1.01 1 1.07 0.93 1.31 
* denotes duration of type 2 diabetes mellitus at study entry 
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Sensitivity Analysis – Prior Parameter 
Results for a model using same structured prior as the main structured model, but with different 
hyperparameter settings. In this model we set the global scale to a much smaller value 
following the suggestions in (S2). We set the expected number of large coefficients to be 𝑝0 = 
15 and used formula 3.12 in the logistic regression setting to derive a global scale which results 
in much stronger expected shrinkage than in the setting of the main model.  
The coefficient posteriors for the top predictors were largely unaffected by this change in prior 
settings. They were insensitive regarding other settings of 𝑝0  as well. The discriminative 
performance was also virtually identical (AUROC 0.62 [0.5, 0.73]). 
 
Supplementary Figure S10: Standardized odds ratios for alternative structured model (different 
hyperparameter) 
Coefficient posteriors for the top 15 predictors of the structured model using prior parameter which lead to much 
stronger expected shrinkage, ranked by marginal means. Point estimate is given by the mean (circle), the median 
is indicated by a vertical line. The thick horizontal line represents the interquartile range, while the thin line 
represents a 95% Bayesian credible interval. Group assignments are indicated by superscript initials (C for 
Clinical, P for Proteomics, M for Metabolomics, L for Lipidomics). 
We studied other prior parameter settings as well (different group and local scales) and 
found no large differences between the models for the top predictors, as long as 
convergence was not hindered by too stringent prior parameters. 
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Sensitivity Analysis – Excluded Baseline eGFR 
Results for a model of the same structure and prior settings as the main structured model but 
excluding baseline eGFR as a variable. Comparing the coefficient posteriors from the main 
model, the large effect of eGFR on the other variables is demonstrated. Excluding this predictor 
led to generally lower effect sizes for most of the other variables, except for KIM1 and 
NTproBNP which were relatively unaffected. This indicated that their contribution to the 
discrimination of eGFR trajectories was largely independent of the presence of baseline eGFR 
in the model. Other protein biomarkers such as HGF and MMP1 showed similar results 
compared to the main model, while the effect of the clinical covariate duration of diabetes 
decreased.  
The discriminative performance of the model was slightly lower than for the main structured 
model (AUROC 0.61 [0.49, 0,72]). 
 
Supplementary Figure S11: Standardized odds ratios for the structured model excluding baseline eGFR 
Coefficient posteriors for the top 15 predictors of the structured model excluding baseline eGFR as covariate, 
ranked by marginal means. Point estimate is given by the mean (circle), the median is indicated by a vertical line. 
The thick horizontal line represents the interquartile range, while the thin line represents a 95% Bayesian credible 
interval. Group assignments are indicated by superscript initials (C for Clinical, P for Proteomics, M for 
Metabolomics, L for Lipidomics). 
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Sensitivity Analysis – Prior Structure 
Results for a model using priors that were uninformed regarding the group structure of the data. 
We set the global scale to one, as in the main structured model.  
The coefficient posteriors for baseline eGFR and KIM1 were largely unaffected by this change. 
Some metabolite and lipid markers increased in marginal effect size which can be explained 
by weaker regularization of these platforms in this model. However, the discriminative 
performance was slightly lower than for the main structured model (AUROC 0.6 [0.48, 0.71]). 
A possible explanation is that these markers showed increased effect sizes due to their 
correlation with the effect of baseline eGFR, while not contributing much to the discrimination 
performance, as indicated by the single group models. Hence, we favoured the main structured 
model over this approach. 
 
Supplementary Figure S12: Standardized odds ratios for model with alternative prior 
Coefficient posteriors for the top 15 predictors of the combined model using a prior uninformed of the structure of 
the data, ranked by marginal means. Point estimate is given by the mean (circle), the median is indicated by a 
vertical line. The thick horizontal line represents the interquartile range, while the thin line represents a 95% 
Bayesian credible interval. Group assignments are indicated by superscript initials (C for Clinical, P for 
Proteomics, M for Metabolomics, L for Lipidomics). 
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Sensitivity Analysis – Principal Components Analysis 
Result for a model based on principal component analysis (PCA) derived predictors. First, a 
PCA was applied to the large metabolite and lipid biomarker platforms. We chose the 15 
principal components (PC) with largest explained variability for both platforms and used 
these instead of individual biomarkers in a model using a prior uninformed of the data 
structure. The rationale was to make the number of predictors for each variable type 
comparable to ensure that this did not influence the results – now all biomarker platforms 
contributed 15 predictors. For metabolites, around 60% of the total variability were captured 
by the 15 PCs, for lipid markers around 75%. 
 
Supplementary Figure S13: Standardized odds ratios for model based on principal components 
Coefficient posteriors for the top 15 predictors of the PCA model, ranked by marginal means. Point estimate is 
given by the mean (circle), the median is indicated by a vertical line. The thick horizontal line represents the 
interquartile range, while the thin line represents a 95% Bayesian credible interval. Group assignments are 
indicated by superscript initials (C for Clinical, P for Proteomics, M for Metabolomics, L for Lipidomics). 
While the clinical covariates and protein markers were largely unaffected by the replacement 
of individual markers with PCA derived predictors, some of the metabolite PCs showed up 
with large marginal effects. These strongly correlated with baseline eGFR and were thus 
reliant on its presence in the model. Overall, the discrimination did not improve when using 
this approach than compared to the individual marker based modelling (AUROC 0.64 [0.55, 
0.74]). Neither did the change in AUROC for submodels (Supplementary Figure S14) including 
fewer markers led to different conclusions than for the main structured model – again, only a 
few predictors sufficed to achieve performance comparable to the full model.  
We therefore favoured the structured model and report it as our main result as its predictions 
were based on individual variables, which eases interpretation and handling of the data. 
Furthermore, it led to more parsimonious results because the PCA derived predictors 
incorporate the whole platform in each single PC. 
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Supplementary Figure S14: Change in model performance using limited predictors in the model based on 
principal components 
Change in model performance when only a limited number of predictors is used to discriminate eGFR trajectory 
groups in the PCA model. Circles depict a point estimate of the cross-validated AUROC (posterior mean), the 
posterior median is indicated by a horizontal bar. The thick line represents the interquartile range and the thin line 
a 95% Bayesian credible interval. The horizontal dashed line indicates the AUROC of the main structured model 
using all 55 variables, which serves as a reference. Modelsize denotes the number of variables in the model, 
starting with the intercept only model, then adding variables in the order as shown in Supplementary Figure S13 
(starting at the top with baseline eGFR). The predictions of the reference model were than projected onto the 
corresponding subset of its variables via the methodology outlined in the Statistical Methods section in order to 
obtain the AUROC values depicted. 
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Model Convergence 
All of the Bayesian models were found to converge satisfactorily by manual inspection of 
several common convergence and efficiency diagnostics at a per-parameter level. The 
parameters most difficult to sample were related to baseline eGFR due to high correlations 
with other variables. Nevertheless, acceptable diagnostics were reached for all parameters. 
Below we give high-level summaries for the main statistics which indicate robust sampling from 
the model posteriors:  
 ?̂? statistics for all parameters summarised by mean and upper 97.5% quantile. A value 
of one indicates convergence. 
 Ratio of estimated effective sample size and number of draws from the posterior 
distribution (𝑁𝑒𝑓𝑓 ratio) for all variables summarised by mean and lower 2.5% quantile. 
Higher values are better and indicate low autocorrelation of the MCMC draws. 
 Percentage of divergent transitions of the Hamiltonian MCMC procedure implemented 
in Stan. Ideally there are no divergent transitions. 
Supplementary Table S3: Bayesian model diagnostics 
High-level summary of standard diagnostics for all of the models presented in this work.  
Model 
?̂? 𝑵𝒆𝒇𝒇 ratio % 
divergent Mean 97.5% quantile Mean 2.5% quantile 
Clinical 1.000 1.001 1.517 0.637 0 
Clinical with 
shrinkage 
1.001 1.004 0.778 0.316 0.002 
Proteomics 1.000 1.003 0.838 0.409 0.002 
Metabolomics 1.000 1.002 0.972 0.605 0 
Lipidomics 1.000 1.002 0.848 0.519 0 
Main 
Structured  
1.000 1.002 0.863 0.489 0 
Structured – 
alternative 
prior 
1.000 1.002 0.869 0.465 0 
Structured – 
excluding 
eGFR 
1.000 1.002 0.933 0.605 0 
Combined 1.000 1.002 0.909 0.510 0 
Combined - 
PCA 
1.000 1.003 0.815 0.392 0.002 
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Stan Implementation of Regularized Horseshoe Priors 
Below is the code used for the combined models with a prior which is uninformed of the 
grouped data structure. The implementation is following the one given in (S2). 
data { 
    int<lower=0> n;  
    int<lower=0> p;  
    int<lower=0, upper=1> group[n];  
    matrix[n,p] X;  
 
    real<lower=0> scale_intercept;  
 
    real<lower=0> scale_global;  
    real<lower=1> df_global;  
    real<lower=1> df_local;  
    real<lower=0> scale_slab;  
    real<lower=0> df_slab;  
} 
parameters { 
    real intercept; 
    vector[p] beta_tilde; 
    real<lower=0> aux1_global; 
    real<lower=0> aux2_global; 
    vector<lower=0>[p] aux1_local; 
    vector<lower=0>[p] aux2_local; 
    real<lower=0> caux; 
} 
transformed parameters { 
    real<lower=0> tau;  
    vector<lower=0>[p] lambda;  
    vector<lower=0>[p] lambda_tilde;  
    real<lower=0> c;  
 
    vector[p] beta;  
    vector[n] mu; 
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    tau = aux1_global * sqrt(aux2_global) * scale_global; 
    c = scale_slab * sqrt(caux); 
     
    lambda = aux1_local .* sqrt(aux2_local); 
    lambda_tilde = sqrt( square(c) * square(lambda) ./ 
                (square(c) + square(tau) * square(lambda)) ); 
    beta = beta_tilde .* lambda_tilde * tau; 
    mu = intercept + X * beta; 
} 
model { 
    target += std_normal_lpdf(beta_tilde); 
    target += std_normal_lpdf(aux1_local); 
    target += inv_gamma_lpdf(aux2_local | 0.5 * df_local, 0.5 * 
df_local); 
    target += std_normal_lpdf(aux1_global); 
    target += inv_gamma_lpdf(aux2_global | 0.5 * df_global, 0.5 * 
df_global); 
    target += inv_gamma_lpdf(caux | 0.5 * df_slab, 0.5 * df_slab); 
 
    target += normal_lpdf(intercept | 0, scale_intercept); 
    target += bernoulli_logit_lpmf(group | mu); 
} 
generated quantities { 
    vector[n] log_lik; 
 
     for (i in 1:n) { 
        log_lik[i] = bernoulli_logit_lpmf(group[i] | mu[i]); 
  } 
} 
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Stan Implementation of the Structured Regularized Horseshoe Priors 
Below is the code used for the combined models with a prior which is adapted to the grouped 
data structure by the use of additional parameters, as described in the extended statistical 
methods (Supplement section 2).  
data { 
    int<lower=0> n;  
    int<lower=0> p;  
    int<lower=0, upper=1> group[n];  
    matrix[n,p] X;  
 
    int<lower=0> p_vgroup; 
    int<lower=0> vgroup[p]; 
 
    real<lower=0> scale_intercept;  
 
    real<lower=0> scale_global;  
    real<lower=1> df_global;  
    real<lower=1> df_local;  
    real<lower=0> scale_slab;  
    real<lower=0> df_slab; 
    real<lower=0> df_vgroup;  
    real<lower=0> scale_vgroup; 
} 
parameters { 
    real intercept; 
    vector[p] beta_tilde; 
    real<lower=0> aux1_global; 
    real<lower=0> aux2_global; 
    vector<lower=0>[p_vgroup] aux1_vgroup; 
    vector<lower=0>[p_vgroup] aux2_vgroup; 
    vector<lower=0>[p] aux1_local; 
    vector<lower=0>[p] aux2_local; 
    real<lower=0> caux; 
} 
transformed parameters { 
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    real<lower=0> tau;  
 
    vector<lower=0>[p_vgroup] tau_vgroup; 
 
    vector<lower=0>[p] lambda;  
    vector<lower=0>[p] lambda_tilde;  
    real<lower=0> c;  
 
    vector[p] beta;  
    vector[n] mu; 
     
    tau = aux1_global * sqrt(aux2_global) * scale_global; 
 
    tau_vgroup = aux1_vgroup .* sqrt(aux2_vgroup) * scale_vgroup; 
 
    c = scale_slab * sqrt(caux); 
    lambda = aux1_local .* sqrt(aux2_local); 
    lambda_tilde = sqrt( square(c) * square(lambda) ./ 
                (square(c) + square(tau) * 
square(tau_vgroup[vgroup]) .* square(lambda)) ); 
 
    beta = beta_tilde .* lambda_tilde .* tau_vgroup[vgroup] * tau; 
    mu = intercept + X * beta; 
} 
model { 
    target += std_normal_lpdf(beta_tilde); 
    target += inv_gamma_lpdf(caux | 0.5 * df_slab, 0.5 * df_slab); 
    target += std_normal_lpdf(aux1_local); 
    target += inv_gamma_lpdf(aux2_local | 0.5 * df_local, 0.5 * 
df_local); 
    target += std_normal_lpdf(aux1_vgroup); 
    target += inv_gamma_lpdf(aux2_vgroup | 0.5 * df_vgroup, 0.5 * 
df_vgroup); 
    target += std_normal_lpdf(aux1_global); 
    target += inv_gamma_lpdf(aux2_global | 0.5 * df_global, 0.5 * 
df_global); 
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    target += normal_lpdf(intercept | 0, scale_intercept); 
    target += bernoulli_logit_lpmf(group | mu); 
} 
generated quantities { 
    vector[n] log_lik; 
 
     for (i in 1:n) { 
        log_lik[i] = bernoulli_logit_lpmf(group[i] | mu[i]); 
  } 
}  
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